letrozole has been researched along with alpha-aminopyridine in 50 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 23 (46.00) | 24.3611 |
| 2020's | 27 (54.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abramson, VG; Arteaga, CL; Balko, JM; Cantley, LC; Forero, A; Isakoff, SJ; Kuba, MG; Li, Y; Mayer, IA; Sanders, ME; Van den Abbeele, AD; Winer, E; Yap, JT | 1 |
| Hattori, T; Nahata, M; Nakagawa, K; Ohnishi, S; Okubo, N; Sadakane, C; Saegusa, Y; Takeda, H; Yamada, C | 1 |
| Bardia, A; Beck, JT; Conte, P; Curigliano, G; Dhuria, S; Di Tomaso, E; Gómez Pardo, P; Hurvitz, SA; Lolkema, MP; Martínez García, M; Meric-Bernstam, F; Miller, M; Penault-Llorca, F; Solovieff, N; Tang, Z | 1 |
| Alba, E; André, F; Arteaga, CL; Bachelot, T; Blackwell, KL; Blau, S; Burdaeva, O; Burris, HA; Cameron, DA; Campone, M; Chan, A; Conte, P; Favret, AM; Germa, C; Grischke, EM; Hart, LL; Hirawat, S; Hortobagyi, GN; Jakobsen, E; Janni, W; Marschner, N; Miller, M; Nusch, A; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Souami, F; Stemmer, SM; Tseng, LM; Verma, S; Villanueva, C; Winer, EP; Wist, E; Xuan, F; Yap, YS; Yardley, D | 1 |
| Akıncı, MB; Bilgin, B; Sendur, MAN; Şener Dede, D; Yalçın, B | 1 |
| Messina, C; Messina, M; Zanardi, E | 1 |
| Barriga, S; Bourayou, N; Campone, M; Chen, SC; Di Leo, A; Forrester, T; Freedman, OC; Frenzel, M; Garnica Jaliffe, G; Goetz, MP; Huober, J; Manso, L; Paluch-Shimon, S; Park, IH; Smith, IC; Sohn, J; Toi, M; Trédan, O | 1 |
| Alba, E; Bachelot, T; Burris, HA; Campone, M; Erdkamp, F; Favret, AM; Germa, C; Hart, LL; Hegg, R; Jakobsen, E; Janni, W; Miller, M; Sonke, GS; Souami, F; Sutradhar, S; Verma, S; Villanueva, C; Wheatley-Price, P; Wist, E | 1 |
| Arteaga, CL; Beck, JT; Cameron, DA; Conte, P; Germa, C; Hart, LL; Hortobagyi, GN; Jakobsen, E; Lindquist, D; Mondal, S; O'Shaughnessy, J; Petrakova, K; Sonke, GS; Souami, F; Villanueva, C | 1 |
| Alba, E; Auñón, PZ; Bachelot, T; Beck, TJ; Campone, M; Diab, S; Esteva, FJ; Gil-Gil, M; Janni, W; Kral, Z; Lopez, R; Miller, M; Pluard, TJ; Richards, P; Ryvo, L; Sutradhar, S; Tsai, M; Ward, P | 1 |
| Alba, E; Burris, HA; Campone, M; Chandiwana, D; Dalal, AA; Janni, W; Monaco, M; O'Shaughnessy, J; Sutradhar, S; Verma, S | 1 |
| Arteaga, CL; Blackwell, KL; Burris, HA; Cameron, DA; Campone, M; Conte, P; Elmeliegy, M; Germa, C; Hortobagyi, GN; Janni, W; Miller, M; Mondal, S; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Stemmer, SM; Su, F; Verma, S; Winer, EP; Yap, YS | 1 |
| Bhattacharyya, D; Bhattacharyya, S; Biskupiak, J; Brixner, D; Dalal, AA; May, JR; Mishra, D; Mistry, R; Oderda, G; Suri, G; Tang, D; Young, K | 1 |
| Babu, KG; Bardia, A; Campos-Gomez, S; Carlson, G; Chow, L; Colleoni, M; De Laurentiis, M; Diaz-Padilla, I; El-Saghir, N; Franke, F; Germa, C; Harbeck, N; Hirawat, S; Hughes, G; Hurvitz, SA; Im, SA; Im, YH; Jung, KH; Kuemmel, S; Lee, KS; Liu, MC; Lu, YS; Sohn, J; Tripathy, D; Villanueva Vazquez, R; Wheatley-Price, P | 1 |
| Bhattacharyya, D; Bhattacharyya, S; Biskupiak, J; Brixner, D; Dalal, AA; Hettle, R; May, JR; Mishra, D; Mistry, R; Oderda, G; Suri, G; Tang, D; Young, K | 1 |
| Afghahi, A; Diamond, JR; Shagisultanova, E; Weiss, J | 1 |
| Ma, J; Peng, L; Tan, C; Wan, X; Zeng, X; Zhang, Y | 1 |
| Long, EF; Zhang, B | 1 |
| Beule, A; Blomqvist, C; Ihalainen, H; Rönty, M; Santti, K; Tarkkanen, M | 1 |
| Chen, Q; Dai, Y; Guo, Q; Lin, X; Xu, R; Ye, L; Zhang, Y | 1 |
| Yardley, DA | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Grellety, T; Meynard, L | 1 |
| Aoun, M; Assi, T; Awada, A; Farhat, F; Kanj, A; Kattan, J; Tarabaih, M | 1 |
| Cristofanilli, M | 1 |
| Bascialla, L; De Giorgi, A; Gallerani, E; Giaquinto, A; Grigioni, E; Gueli, R; Marrazzo, C; Nigro, O; Pinotti, G; Vallini, I | 1 |
| Basile, D; Buzzo, M; Gagno, S; Guardascione, M; Iacuzzi, V; Marangon, E; Orleni, M; Pelizzari, G; Poetto, AS; Posocco, B; Puglisi, F; Toffoli, G; Zanchetta, M | 1 |
| Dhakne, P; Sahu, AK; Sengupta, P; Sharma, MK | 1 |
| Asmus, EJ; Block, MS; Butler, KA; Camoriano, JK; Colon-Otero, G; Copland, JA; Dinh, TA; Foster, NR; Glaser, GE; Hou, X; Jatoi, A; Langstraat, CL; Robertson, MW; Wahner Hendrickson, A; Weroha, SJ; Zanfagnin, V | 1 |
| Canova, C; Klausner, G; Troussier, I | 1 |
| Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M | 1 |
| André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK | 1 |
| Erdal, GS; Gulturk, I; Ozmen, A; Tacar, SY; Tural, D; Yilmaz, M | 1 |
| Adamo, B; Bellet, M; Brasó-Maristany, F; Carey, LA; Chic, N; Ciruelos, E; Cortés, J; Galván, P; Gavilá, J; González-Farré, B; Martínez, D; Martínez-Sáez, O; Muñoz, M; Oliveira, M; Pascual, T; Pernas, S; Perou, CM; Prat, A; Sanfeliu, E; Saura, C; Schettini, F; Soberino, J; Vidal, M | 1 |
| Abbas, H; Lim, Z; Malik, AA; Oo, ZM | 1 |
| Azim, HA; Bofill, JS; Borstnar, S; Campone, M; Chatterjee, S; Ciruelos, E; Cottu, P; De Laurentiis, M; Dent, S; Jacot, W; Lu, J; Martin, M; Menon-Singh, L; Ring, A; Warner, E; Wu, J; Zamagni, C; Zhou, K | 1 |
| Goetz, MP; Kawaguchi, T; Mori, J; Takahashi, M; Tanizawa, Y; Toi, M; Tokunaga, E; van der Walt, JS | 1 |
| Alberti, M; Basile, D; Buzzo, M; Canil, G; Gagno, S; Gerratana, L; Guardascione, M; Iacuzzi, V; Montico, M; Orleni, M; Pelizzari, G; Poetto, AS; Posocco, B; Puglisi, F; Toffoli, G; Zanchetta, M | 1 |
| Abdel-Razeq, H; Cardoso, F; Cottu, P; De Laurentiis, M; Marchetti, P; Martín, M; Menon-Singh, L; Ring, A; Salvador Bofill, J; Wu, J | 1 |
| Agterof, M; Brown-Glaberman, U; Campone, M; Chatterjee, S; De Laurentiis, M; Kudryavcev, I; Martín, M; Menon-Singh, L; Palácová, M; Wu, J; Zamagni, C | 1 |
| André, F; Arteaga, CL; Burris, HA; Cameron, DA; Campone, M; Chakravartty, A; Conte, P; Hart, L; Hortobagyi, GN; Janni, W; Le Gac, F; O'Shaughnessy, J; Petrakova, K; Serra, P; Sonke, GS; Stemmer, SM; Taran, T; Winer, EP; Yap, YS; Zarate, JP | 1 |
| Çelik, H; Çil, T; Duman, BB; Erçolak, V; Eser, K; İnal, A; Kesen, O; Köşeci, T; Önder, AH; Öztürk, B; Sezer, E | 1 |
| Beniak, J; Borstnar, S; Gal-Yam, EN; Kudela, P; Palacova, M; Papazisis, K; Rubovszky, G; Timcheva, C; Łacko, A | 1 |
| Arumí, M; Ciruelos, E; Falato, C; Ferrer, N; Gavilá, J; Gil-Gil, M; Gómez, G; González-Santiago, S; Hernando, C; Izarzugaza, Y; Montaño, A; Muñoz, M; Najera-Zuloaga, J; Paré, L; Pascual, T; Prat, A; Saura, C; Villacampa, G; Villagrasa, P | 1 |
| Alvarez Lopez, IM; Anton Torres, A; Barnadas Molins, A; Bellet Ezquerra, M; Cantos Sanchez de Ibargüen, B; Ciruelos Gil, EM; de Casa, S; De la Cruz Merino, L; De la Haba-Rodriguez, J; de Toro Salas, R; Delgado Mingorance, JI; Diaz Fernandez, N; Galve Calvo, E; Gavila Gregori, J; Gimeno, A; Gonzalez-Santiago, S; Hernando Melia, C; Jiménez-Rodriguez, B; Martin, M; Martínez Jañez, N; Moreno Anton, F; Quiroga Garcia, V; Rodriguez Sanchez, CA; Salvador Bofill, J; Vicente Rubio, E; Vidal, M; Villanueva Vazquez, R | 1 |
| Allegrini, G; Arpino, G; Benelli, M; Bianchi, GV; Bianchini, G; Caputo, R; Castelletti, D; Cazzaniga, ME; Colleoni, M; De Laurentiis, M; Del Mastro, L; Di Marino, M; Guarneri, V; Malorni, L; Montemurro, F; Orditura, M; Paris, I; Puglisi, F; Tamberi, S; Zamagni, C; Zambelli, A | 1 |
| Hayashi, M; Hirata, A; Kimura, K; Morita, S; Takashima, Y; Terasawa, R | 1 |
| André, F; Arteaga, CL; Babbar, N; Bardia, A; Chia, S; Hortobagyi, G; Lteif, A; Lu, YS; Neven, P; Slamon, D; Solovieff, N; Su, F; Taran, T; Tripathy, D | 1 |
| Aogi, K; Futamura, M; Hosonaga, M; Imamura, CK; Iwasa, T; Iwata, H; Kawabata, H; Masuda, J; Masuda, N; Matsumoto, K; Miura, S; Mukohara, T; Sakai, H; Takahashi, M; Takano, T; Tanabe, Y; Tomioka, N; Tsurutani, J; Yamochi, T; Yasojima, H; Yoshimura, K | 1 |
6 review(s) available for letrozole and alpha-aminopyridine
| Article | Year |
|---|---|
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinases; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Triazoles | 2017 |
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Piperazines; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2021 |
CDK4/6 inhibitor-induced colitis: a case report and review of the literature.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colitis; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Letrozole; Purines; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
25 trial(s) available for letrozole and alpha-aminopyridine
| Article | Year |
|---|---|
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Letrozole; Middle Aged; Morpholines; Multimodal Imaging; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; Tomography, X-Ray Computed; Triazoles | 2014 |
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin D2; Cyclin D3; Cyclin E; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; DNA, Neoplasm; Female; Gene Expression; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Oncogene Proteins; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retinoblastoma Protein; Signal Transduction; Triazoles | 2016 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2016 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptor, ErbB-2; Survival Rate; Treatment Outcome; Triazoles | 2017 |
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Nitriles; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2018 |
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Female; Humans; Incidence; Kaplan-Meier Estimate; Letrozole; Leukopenia; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Time Factors | 2018 |
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Young Adult | 2018 |
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Postmenopause; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Young Adult | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Humans; Letrozole; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Prognosis; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2018 |
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Topics: Administration, Oral; Adult; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Internationality; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Premenopause; Prognosis; Proportional Hazards Models; Purines; Survival Analysis; Tamoxifen; Treatment Outcome; Young Adult | 2018 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogens; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptor, ErbB-2; Tamoxifen; Young Adult | 2019 |
Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Purines; Pyridines; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Viscera | 2020 |
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Purines; Receptors, Estrogen | 2020 |
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Receptor, ErbB-2; Treatment Outcome | 2021 |
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; MCF-7 Cells; Menopause; Middle Aged; Neoadjuvant Therapy; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Transcriptome | 2021 |
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2021 |
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Female; Humans; Japan; Letrozole; Middle Aged; Progression-Free Survival; Quality of Life; Receptors, Progesterone | 2022 |
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hormones; Humans; Letrozole; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2022 |
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Humans; Letrozole; Male; Neutropenia; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2022 |
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Intention to Treat Analysis; Letrozole; Middle Aged; Neoplasm Grading; Neutropenia; Purines; Receptor, ErbB-2; Receptors, Estrogen; Survival Analysis | 2022 |
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Male; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2022 |
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
Topics: Aminopyridines; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Purines; Quality of Life; Taxoids | 2022 |
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neutropenia; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2022 |
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Female; Humans; Letrozole; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Thymidine Kinase | 2023 |
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
Topics: Aminopyridines; Antibodies; Benzimidazoles; Breast Neoplasms; Female; Humans; Letrozole; Nivolumab | 2023 |
19 other study(ies) available for letrozole and alpha-aminopyridine
| Article | Year |
|---|---|
Serotonin 2C receptor contributes to gender differences in stress-induced hypophagia in aged mice.
Topics: Age Factors; Aminopyridines; Animals; Anorexia; Aromatase Inhibitors; Brain; Corticosterone; ERRalpha Estrogen-Related Receptor; Feeding Behavior; Female; Ghrelin; Indoles; Letrozole; Male; Mice; Nitriles; Paraventricular Hypothalamic Nucleus; Phenols; Piperazines; Pyrazines; Pyrazoles; Receptor, Serotonin, 5-HT2C; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Sex Factors; Stress, Psychological; Triazoles | 2015 |
Ribociclib Lengthens Breast Cancer Survival.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Purines; Treatment Outcome; Triazoles | 2016 |
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Letrozole; Models, Biological; Models, Economic; Nitriles; Piperazines; Postmenopause; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles; United States | 2018 |
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Budgets; Female; Humans; Letrozole; Postmenopause; Purines; Receptor, ErbB-2; Receptors, Estrogen; United States | 2018 |
Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Carcinoma, Lobular; Colonic Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2018 |
Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Progression-Free Survival; Purines; Quality-Adjusted Life Years; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Markov Chains; Models, Economic; Piperazines; Purines; Pyridines; Quality of Life; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2019 |
The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report.
Topics: Abdominal Neoplasms; Adenomatous Polyposis Coli; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fibromatosis, Aggressive; Goserelin; Humans; Letrozole; Protein Kinase Inhibitors; Purines; Young Adult | 2019 |
CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity.
Topics: Alanine Transaminase; Aminopyridines; Aromatase Inhibitors; Aspartate Aminotransferases; Bone Neoplasms; Breast Neoplasms; Carcinoma, Lobular; Chemical and Drug Induced Liver Injury; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Substitution; Drug Therapy, Combination; Female; Humans; Letrozole; Middle Aged; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2020 |
Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Humans; Letrozole; Liver; Middle Aged; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Zoledronic Acid | 2020 |
Time for a shift in molecular down staging in luminal breast cancer.
Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Letrozole; Postmenopause; Purines; Receptor, ErbB-2; Receptors, Progesterone | 2020 |
Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application.
Topics: Aminopyridines; Chromatography, High Pressure Liquid; Drug Stability; Humans; Letrozole; Piperazines; Purines; Pyridines; Reproducibility of Results; Tandem Mass Spectrometry | 2020 |
Simultaneous quantification of abemaciclib and letrozole in rat plasma: method development, validation and pharmacokinetic application.
Topics: Aminopyridines; Animals; Benzimidazoles; Chromatography, High Pressure Liquid; Female; Letrozole; Limit of Detection; Linear Models; Rats; Rats, Sprague-Dawley; Reproducibility of Results | 2020 |
Complete response of leptomeningeal carcinomatosis secondary to breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Letrozole; Meningeal Carcinomatosis; Middle Aged; Radiotherapy, Adjuvant | 2020 |
Ribociclib induced acute kidney injury: A case report.
Topics: Acute Kidney Injury; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Purines; Receptors, Estrogen | 2021 |
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Chromatography, Liquid; Dried Blood Spot Testing; Drug Monitoring; Female; Humans; Letrozole; Piperazines; Purines; Pyridines; Tandem Mass Spectrometry | 2021 |
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; Letrozole; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Retrospective Studies | 2022 |
[ESR1 Mutation-Positive Recurrent Breast Cancer Successfully Treated with Letrozole plus Abemaciclib].
Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Letrozole; Mutation | 2023 |
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Prospective Studies; Receptor, ErbB-2 | 2023 |